|
1
|
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
|
Blood
|
2005
|
2.06
|
|
2
|
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.
|
Blood
|
2003
|
2.00
|
|
3
|
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
|
J Clin Oncol
|
2007
|
1.94
|
|
4
|
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
|
Haematologica
|
2007
|
1.59
|
|
5
|
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
|
Haematologica
|
2002
|
1.47
|
|
6
|
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
|
Haematologica
|
2004
|
1.38
|
|
7
|
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
|
Blood
|
2002
|
1.15
|
|
8
|
Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
|
Eur J Nucl Med Mol Imaging
|
2006
|
1.02
|
|
9
|
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
|
Eur J Haematol
|
2006
|
0.99
|
|
10
|
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
|
Blood
|
2006
|
0.98
|
|
11
|
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
|
Eur J Haematol
|
2005
|
0.91
|
|
12
|
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report and results from a cytoflourimetric assay of platelet fibrinogen receptor.
|
J Clin Oncol
|
2013
|
0.86
|
|
13
|
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
|
Eur J Haematol
|
2004
|
0.85
|
|
14
|
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.
|
J Clin Oncol
|
2006
|
0.83
|
|
15
|
Reversible, PET-positive, generalized lymphadenopathy and splenomegaly during high-dose interferon-alpha-2b adjuvant therapy for melanoma.
|
J Immunother
|
2008
|
0.75
|
|
16
|
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
|
Ann Hematol
|
2006
|
0.75
|
|
17
|
Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G).
|
Am J Hematol
|
2010
|
0.75
|